What type of study is this?

August 20, 2025Hematological OncologyOpen Access

Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

View Full Paper

Ask AI

Bookmark

Loncastuximab shows manageable adverse events, including edema and rash, improving patient care in DLBCL.
The most common adverse events include edema and rash, occurring within the first 4 doses, indicating a need for monitoring.
Online survey among lymphoma specialists assessed management practices for Loncastuximab-related adverse events and developed care strategies.
Effective management strategies include delaying therapy or prescribing medications like diuretics and steroids to mitigate adverse effects.

No takes yet. Share an insight, caveat, or question.

Survey reports on adverse events management in diffuse large B-cell lymphoma, suggesting improved strategies for Loncastuximab treatment.

Epperla et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark